Yong-seong Kim

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
AIM Recent evidence suggests that aldo-keto reductase family 1 B10 (AKR1B10) may be a potential diagnostic or prognostic marker of human tumors, and that AKR1B10 inhibitors offer a promising choice for treatment of many types of human cancers. The aim of this study was to identify novel chemical scaffolds of AKR1B10 inhibitors using in silico approaches. (More)
  • 1